{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:18:57Z","timestamp":1791674337653,"version":"4.3.4"},"reference-count":61,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["214710"],"award-info":[{"award-number":["214710"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2022,7,23]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Lupus nephritis (LN) is more prevalent in patients with SLE of Asian ethnicity than in Caucasian patients. Belimumab became available in Japan in 2017 to treat patients with SLE, including those with LN. In the BLISS-LN trial (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01639339\">NCT01639339<\/jats:ext-link>\n                      ), belimumab showed a favourable effect on renal outcomes when combined with standard therapy (ST) starting at the induction treatment phase for active LN, but real-world effectiveness of belimumab in LN has not been extensively studied. Here we describe the protocol for the MOONLIGHT (post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide ReGistry (LUNA) coHorT) study, which will use data from a Japan postmarketing surveillance study and the Lupus Registry of Nationwide Institutions (LUNA) to evaluate the real-world effectiveness of belimumab plus ST versus ST alone in patients with a history of active LN who are not in the induction phase.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multicentre, retrospective, observational study (GSK Study 214710) will enrol adults with SLE and a history of active LN, holding \u22653 years of complete follow-up data from the initiation of belimumab (no continuous treatment required). Data for patients with belimumab plus ST treatment (postmarketing registry data, belimumab cohort) will be compared with those for patients with ST only treatment (LUNA data, comparison cohort). Patients who discontinue\/initiate belimumab after the start of the follow-up may be included in the comparison\/belimumab cohort, respectively. The primary endpoint will be the occurrence of renal flares, for which belimumab\u2019s effectiveness will be estimated using a marginal structural model to consider time-dependent treatment and confounding factors. Secondary endpoints will include change in corticosteroid dose, renal disease activity, extrarenal disease activity, disease severity\/activity biomarkers, LN class changes, end-stage kidney disease events and hospitalisations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study will be conducted according to the Declaration of Helsinki and the local ethical guidelines. Findings will be submitted to peer-reviewed journals and presented at scientific meetings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2022-000746","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T12:01:11Z","timestamp":1662033671000},"page":"e000746","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01639339","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03370263","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-0818","authenticated-orcid":false,"given":"Kenei","family":"Sada","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Kochi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kurita","sequence":"additional","affiliation":[{"name":"Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), Fukushima Medical University Hospital, Fukushima, Japan"},{"name":"Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Noma","sequence":"additional","affiliation":[{"name":"Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes Division, GSK K.K, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1659-0004","authenticated-orcid":false,"given":"Holly","family":"Quasny","sequence":"additional","affiliation":[{"name":"Clinical Sciences, GSK, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6031","authenticated-orcid":false,"given":"Roger A","family":"Levy","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela R","family":"Jones-Leone","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-1396","authenticated-orcid":false,"given":"Kerry","family":"Gairy","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes Division, GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan"},{"name":"Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan"},{"name":"Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"2026052805000609000_9.1.e000746.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev311"},{"key":"2026052805000609000_9.1.e000746.2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05780616"},{"key":"2026052805000609000_9.1.e000746.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01118-X"},{"key":"2026052805000609000_9.1.e000746.4","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310374305"},{"key":"2026052805000609000_9.1.e000746.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.39594"},{"key":"2026052805000609000_9.1.e000746.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker101"},{"key":"2026052805000609000_9.1.e000746.7","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320932219"},{"key":"2026052805000609000_9.1.e000746.8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040415"},{"key":"2026052805000609000_9.1.e000746.9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/1756-185X.13363","article-title":"Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: a retrospective, observational study","volume":"21","author":"Tanaka","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2026052805000609000_9.1.e000746.10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000430458","article-title":"Lupus nephritis in Asia: clinical features and management","volume":"1","author":"Yap","year":"2015","journal-title":"Kidney Dis"},{"key":"2026052805000609000_9.1.e000746.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205171"},{"key":"2026052805000609000_9.1.e000746.12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080828"},{"key":"2026052805000609000_9.1.e000746.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031850"},{"key":"2026052805000609000_9.1.e000746.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299"},{"key":"2026052805000609000_9.1.e000746.15","unstructured":"GlaxoSmithKline . Belimumab prescribing information. Available: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MG-IFU.PDF [Accessed February 2022]."},{"key":"2026052805000609000_9.1.e000746.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2026052805000609000_9.1.e000746.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2026052805000609000_9.1.e000746.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"2026052805000609000_9.1.e000746.19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001629","article-title":"Long-Term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea","volume":"7","author":"Tanaka","year":"2021","journal-title":"RMD Open"},{"key":"2026052805000609000_9.1.e000746.20","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312465781"},{"key":"2026052805000609000_9.1.e000746.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"2026052805000609000_9.1.e000746.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.027"},{"key":"2026052805000609000_9.1.e000746.23","first-page":"191","article-title":"Risk factors for chronic damage accumulation across different onset eras in systemic lupus erythematosus: a cross-sectional analysis of a Lupus Registry of Nationwide Institutions (LUNA)","volume":"74","author":"Ohashi","year":"2020","journal-title":"Acta Med Okayama"},{"key":"2026052805000609000_9.1.e000746.24","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211006790"},{"key":"2026052805000609000_9.1.e000746.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2026052805000609000_9.1.e000746.26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/0961203319898766","article-title":"Damage accrual related to pregnancies before and after diagnosis of systemic lupus erythematosus: a cross-sectional and nested case-control analysis from a lupus registry","volume":"29","author":"Morishita","year":"2020","journal-title":"Lupus"},{"key":"2026052805000609000_9.1.e000746.27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"2019","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026052805000609000_9.1.e000746.28","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"2026052805000609000_9.1.e000746.29","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308100481"},{"key":"2026052805000609000_9.1.e000746.30","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.220"},{"key":"2026052805000609000_9.1.e000746.31","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"2026052805000609000_9.1.e000746.32","doi-asserted-by":"publisher","DOI":"10.1159\/000362285"},{"key":"2026052805000609000_9.1.e000746.33","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e31818f69ce"},{"key":"2026052805000609000_9.1.e000746.34","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"2026052805000609000_9.1.e000746.35","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"2026052805000609000_9.1.e000746.36","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05040513"},{"key":"2026052805000609000_9.1.e000746.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170226"},{"key":"2026052805000609000_9.1.e000746.38","doi-asserted-by":"publisher","DOI":"10.1080\/08860220802353843"},{"key":"2026052805000609000_9.1.e000746.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.08.045"},{"key":"2026052805000609000_9.1.e000746.40","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1756-185X.13274","article-title":"Outcome and predictors of renal survival in patients with lupus nephritis: comparison between cyclophosphamide and mycophenolate mofetil","volume":"21","author":"Joo","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2026052805000609000_9.1.e000746.41","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20683"},{"key":"2026052805000609000_9.1.e000746.42","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21597"},{"key":"2026052805000609000_9.1.e000746.43","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102533"},{"key":"2026052805000609000_9.1.e000746.44","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006090992"},{"key":"2026052805000609000_9.1.e000746.45","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs073"},{"key":"2026052805000609000_9.1.e000746.46","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314536246"},{"key":"2026052805000609000_9.1.e000746.47","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2081oa"},{"key":"2026052805000609000_9.1.e000746.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010193431604"},{"key":"2026052805000609000_9.1.e000746.49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2005.00444.x"},{"key":"2026052805000609000_9.1.e000746.50","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr484"},{"key":"2026052805000609000_9.1.e000746.51","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nep.12863","article-title":"Clinical and histological features of lupus nephritis in Japan: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR)","volume":"22","author":"Hiromura","year":"2017","journal-title":"Nephrology"},{"key":"2026052805000609000_9.1.e000746.52","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317717082"},{"key":"2026052805000609000_9.1.e000746.53","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/13696998.2020.1740236","article-title":"Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study","volume":"23","author":"Miyazaki","year":"2020","journal-title":"J Med Econ"},{"key":"2026052805000609000_9.1.e000746.54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2026052805000609000_9.1.e000746.55","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex286"},{"key":"2026052805000609000_9.1.e000746.56","unstructured":"Japan College of Rheumatology . A treatment guideline for systemic lupus erythematosus 2019."},{"key":"2026052805000609000_9.1.e000746.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031855"},{"key":"2026052805000609000_9.1.e000746.58","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201940"},{"key":"2026052805000609000_9.1.e000746.59","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310388445"},{"key":"2026052805000609000_9.1.e000746.60","article-title":"Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus","author":"Miyazaki","year":"2021","journal-title":"Rheumatology"},{"key":"2026052805000609000_9.1.e000746.61","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2022-000746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:00:19Z","timestamp":1779969619000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2022-000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/lupus-2022-000746"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2022-000746","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}